Ectin Research AB (XSAT:ECTIN B) Debt-to-Equity : 0.40 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB Debt-to-Equity?

Ectin Research AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Ectin Research AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.76 Mil. Ectin Research AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr1.90 Mil. Ectin Research AB's debt to equity for the quarter that ended in Mar. 2024 was 0.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ectin Research AB's Debt-to-Equity or its related term are showing as below:

XSAT:ECTIN B' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.4
Current: 0.4

During the past 4 years, the highest Debt-to-Equity Ratio of Ectin Research AB was 0.40. The lowest was 0.02. And the median was 0.04.

XSAT:ECTIN B's Debt-to-Equity is ranked worse than
70.22% of 1061 companies
in the Biotechnology industry
Industry Median: 0.14 vs XSAT:ECTIN B: 0.40

Ectin Research AB Debt-to-Equity Historical Data

The historical data trend for Ectin Research AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ectin Research AB Debt-to-Equity Chart

Ectin Research AB Annual Data

Trend

Aug19

Aug20

Dec22

Dec23

Debt-to-Equity

0.07

0.08

0.03

0.17

Ectin Research AB Quarterly Data
	Aug19	Aug20	Mar21	Sep21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial								0.04	0.04	0.05	0.17	0.40

Competitive Comparison of Ectin Research AB's Debt-to-Equity

For the Biotechnology subindustry, Ectin Research AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ectin Research AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ectin Research AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ectin Research AB's Debt-to-Equity falls into.

Ectin Research AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ectin Research AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.73)	/	4.199
	=	0.17

Ectin Research AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.76)	/	1.9
	=	0.40

Ectin Research AB (XSAT:ECTIN B) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ectin Research AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ectin Research AB (XSAT:ECTIN B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Pepparedsleden 1, Molndal, SWE, 431 83

Website

https://www.ectinresearch.com

Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB (XSAT:ECTIN B) Headlines

No Headlines